logo
Plus   Neg
Share
Email

Intrepid Potash Turns To Profit In Q4, Adj. Earnings Beat View - Quick Facts

Intrepid Potash Inc. (IPI), a producer of potash and langbeinite products, on Tuesday reported a turnaround to profit in the fourth quarter on higher sales. Adjusted earnings per share beat analysts' estimates.

The company's net income for the fourth quarter was $7.63 million or $0.06 per share, compared to net loss of $1.64 million or $0.01 per share in the same period last year.

The company noted that the improvement in net income was driven by increased water sales, higher average net realized sales prices for potash and Trio®, and reduced lower of cost or net realizable value adjustments related to international Trio shipments.

Adjusted earnings for the quarter were $0.06 per share, compared to $0.03 per share in the prior-year quarter.

Sales for the quarter rose to $54.36 million from $42.58 million in the year-ago period.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.03 per share for the quarter on revenues of $36.19 million. Analysts' estimates typically exclude special items.

"Fourth quarter results benefited from strong potash sales, higher market prices for potash and Trio, and another quarter of solid demand for oilfield solutions. The fourth quarter also marks the first quarter of positive gross margin for our Trio segment since 2016 as we saw the benefits of a focused international strategy and increased byproduct sales," said Bob Jornayvaz, Intrepid's Executive Chairman, President, and CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
Follow RTT